The Pharmacologic and Clinical Effects of Medical Cannabis
Top Cited Papers
- 5 February 2013
- journal article
- review article
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 33 (2), 195-209
- https://doi.org/10.1002/phar.1187
Abstract
Cannabis, or marijuana, has been used for medicinal purposes for many years. Several types of cannabinoid medicines are available in the United States and Canada. Dronabinol (schedule III), nabilone (schedule II), and nabiximols (not U.S. Food and Drug Administration approved) are cannabis‐derived pharmaceuticals. Medical cannabis or medical marijuana, a leafy plant cultivated for the production of its leaves and flowering tops, is a schedule I drug, but patients obtain it through cannabis dispensaries and statewide programs. The effect that cannabinoid compounds have on the cannabinoid receptors (CB1 and CB2) found in the brain can create varying pharmacologic responses based on formulation and patient characteristics. The cannabinoid Δ9‐tetrahydrocannabinol has been determined to have the primary psychoactive effects; the effects of several other key cannabinoid compounds have yet to be fully elucidated. Dronabinol and nabilone are indicated for the treatment of nausea and vomiting associated with cancer chemotherapy and of anorexia associated with weight loss in patients with acquired immune deficiency syndrome. However, pain and muscle spasms are the most common reasons that medical cannabis is being recommended. Studies of medical cannabis show significant improvement in various types of pain and muscle spasticity. Reported adverse effects are typically not serious, with the most common being dizziness. Safety concerns regarding cannabis include the increased risk of developing schizophrenia with adolescent use, impairments in memory and cognition, accidental pediatric ingestions, and lack of safety packaging for medical cannabis formulations. This article will describe the pharmacology of cannabis, effects of various dosage formulations, therapeutics benefits and risks of cannabis for pain and muscle spasm, and safety concerns of medical cannabis use.This publication has 76 references indexed in Scilit:
- Medial temporal structures and memory functions in adolescents with heavy cannabis useJournal of Psychiatric Research, 2011
- “But my Doctor Recommended Pot”: Medical Marijuana and the Patient–Physician RelationshipJournal of General Internal Medicine, 2011
- Effects of cannabis on cognitive function in patients with multiple sclerosisNeurology, 2011
- Pharmacological Treatment of Painful HIV-Associated Sensory Neuropathy: A Systematic Review and Meta-Analysis of Randomised Controlled TrialsPLOS ONE, 2010
- International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1and CB2Published by American Society for Pharmacology & Experimental Therapeutics (ASPET) ,2010
- Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental modelsBritish Journal of Pharmacology, 2010
- Comparison of subjective, pharmacokinetic, and physiological effects of marijuana smoked as joints and bluntsDrug and Alcohol Dependence, 2009
- Biomarkers for the effects of cannabis and THC in healthy volunteersBritish Journal of Clinical Pharmacology, 2008
- Smoked Medicinal Cannabis for Neuropathic Pain in HIV: A Randomized, Crossover Clinical TrialNeuropsychopharmacology, 2008
- A possible role for the endocannabinoid system in the neurobiology of depressionClinical Practice and Epidemiology in Mental Health, 2007